At the IGTP TODAY

News

- Campus Can Ruti, Outreach

Can Ruti welcomes students from Badalona for the Science Week

Nearly 200 baccalaureate and vocational training students from the Badalona institutes visited the centres at the Can Ruti Campus. The event "Open House, get to know the Can Ruti Campus up close", organised by the Badalona Education Service and IGTP, in coordination with other institutions on the Campus, has become a flagship initiative of the Science Week.

ICS 2024 Career Achievement Award and Best Research Poster at the 15th ICS Conference, focused on respiratory diseases

Advanced therapies and precision medicine, artificial intelligence applied to respiratory diseases, the importance of networking, or the challenges of social care and ageing in the field of research were some of the topics discussed during the 15th edition. The ICS Research Awards were also presented during the event, with the majority being awarded to female researchers this year.

Translational Program in Cancer Research II Workshop: A hub for research and collaboration

The second CARE Workshop, held on 9-10 October, brought together more than 70 researchers from across the cancer research community at the Can Ruti Biomedical Campus for two days of scientific exchange. The event served as a platform for sharing the current cancer research being developed on the Campus and fostering stronger connections among researchers.

Menarini and the Germans Trias i Pujol Research Institute sign an agreement to promote research projects

The organisations are collaborating on two studies in the field of severe Legionella infections and antibiotic resistance. Both projects have been presented by IGTP researchers within the framework of the "Scientific exchanges: join us" program, an initiative by Menarini to share progress and strengthen partnerships in research.

- Campus Can Ruti, Research

New study finds a promising combined therapy for multiple sclerosis

Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.